FDA Brief

Warning letters Drugs

FDA warning letter to

Dibar Nutricional S. de R.L. de C.V.

High riskIssued Mar 10, 2021Posted Mar 16, 2021Center for Drug Evaluation and Research

Dibar Nutricional's OTC drugs drew FDA CGMP violations and an import alert over missing testing.

What happened

FDA reviewed records Dibar Nutricional submitted in response to an April 22, 2020, request for records under section 704(a)(4) of the FD&C Act for its facility. FDA found significant CGMP violations for finished OTC drug products, including missing identity testing of incoming components, no finished-product release testing, an inadequate stability program, and unqualified equipment. FDA also stated that all drugs and drug products made by the firm were placed on Import Alert 66-40 on November 6, 2020.

What FDA found

  1. The firm did not test each incoming component lot to verify identity; it relied on random supplier sampling and sensory evaluation.

    21 CFR 211.84(d)(1)
  2. The firm released OTC drugs without full finished-product testing for identity and strength of active ingredients before distribution.

    21 CFR 211.165(a)
  3. The firm lacked an adequate stability program, including testing in the marketed container-closure system and testing active ingredients and degradation products over shelf life.

    21 CFR 211.166(a)
  4. The firm lacked installation and operation qualification documents for manufacturing equipment and recent calibration information, including for scales used to weigh active ingredients.

    21 CFR 211.63

What FDA wants

Respond in writing within 15 working days with corrective actions and supporting records; if corrective actions cannot be completed, state the reasons and a completion schedule. FDA also strongly recommends engaging a qualified CGMP consultant.

Who should pay attention

  • brands that buy OTC drugs from this contract manufacturer
  • US importers and distributors of Dibar drug products
  • companies relying on supplier certificates of analysis for component identity

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk